Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its ...